Abstract 472P
Background
The overexpression of human epidermal growth factor receptor Her2 is associated with a more aggressive cancer phenotype. We have formulated a Her2 vaccine (HER-Vaxx), comprising B-cell peptide from the trastuzumab binding site, inducing anti-tumor immune responses and immunological memory in pre-clinical and clinical investigations. In the phase 1b evaluation (NCT02795988) of the vaccine, one patient had progressed with a new metastatic lesion with no Her2 expression. The vaccine’s pre-clinical evaluation was shown to significantly reduce Her2 lung metastases size in a murine model, and was associated with Her2 loss and upregulation of tumoral PD-L1 expression. In light of the preclinical observation, the patient’s primary tumor at the pre- and post-treatment time points was evaluated with regard to expression levels of Her2 and PD-L1.
Methods
Biopsies of the patient’s primary tumor from the pre- and post-treatment time points were evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for Her2, and combined positive score (CPS) for PD-L1 expression. The murine Her2 lung metastases model was employed to further investigate the proteins’ expression association.
Results
The assessment of the patient’s primary tumor biopsies indicated Her2 3+ (IHC), Her2 /CEP17 ratio of 4.98 (FISH) and 0% PD-L1 CPS at the pre-treatment time point. At the post-treatment time point, the primary tumor’s assessment showed a loss of Her2 expression: 0 (IHC) and Her2 /CEP17 ratio of 1.63 (FISH), with 5% PD-L1 (CPS) expression. In the mouse model, vaccination with HER-Vaxx resulted in a significant reduction of Her2 and upregulation of PD-L1 expression 6 weeks or longer after tumor cell implantation, at transcriptional and translational levels in the same tumors of the metastasized lungs of the vaccinated mice.
Conclusions
These results strongly suggest an immune evasive tumor cell response with an upregulation of PD-L1 expression in both, the clinical and preclinical settings. A combination therapy targeting both Her2 and PD-L1 in Her2-overexpressing tumors might efficiently prevent metastasis formation and immune evasion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical University of Vienna; Imugene Limited.
Funding
Has not received any funding.
Disclosure
N. Ede: Financial Interests, Personal, Full or part-time Employment: Imugene Limited. C. Zielinski: Other, Personal, Other, Consultancies and Speaker’s Honoraria: Athenex, MSD, AstraZeneca, Servier, Eli Lilly; Other, Personal, Other, Patents: Imugene Limited; Other, Institutional, Other: BMS, MSD, Pfizer, AstraZeneca, Merck KgA, Servier, Eli Lilly, Takeda, Daiichi Sankyo, Roche, Boehringer Ingelheim, Celgene, Halozyme, Amgen. A. Good: Other, Personal, Other: Imugene Limited. U. Wiedermann: Other, Personal, Other, CSO of Imugene until September 2018: Imugene Limited; Other, Institutional, Other, Funding to the Institute: MSD, Pfizer, Themis. All other authors have declared no conflicts of interest.
Resources from the same session
1266P - Prediction of lung cancer risk in ground-glass nodules using deep learning from CT images
Presenter: Anil Vachani
Session: Poster session 04
1267P - Enhancing pulmonary nodule diagnosis: A combinatorial model of cfDNA methylation, plasma proteins and LDCT imaging
Presenter: Meng Yang
Session: Poster session 04
1268P - Liquid biopsy and CT-based multi-omics fusion enhances differential diagnosis of early-stage lung adenocarcinoma
Presenter: Yanwei Zhang
Session: Poster session 04
1269P - Machine learning model for predicting lung cancer recurrence after surgical treatment: A retrospective study using NLST and European hospital data
Presenter: Ann Valter
Session: Poster session 04
1272P - Postoperative survival prediction in non-small cell lung cancer patients based on driver genotypes
Presenter: Huiting Wang
Session: Poster session 04
1273P - The prognostic value evaluation of a tissue Comprehensive Genomic Profiling (CGP)-informed personalized MRD detection assay in NSCLC
Presenter: Wei Gao
Session: Poster session 04
1274P - Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer
Presenter: Kyungmi Yang
Session: Poster session 04
1275P - Genomic analysis of lung adenocarcinoma with micropapillary component: Identification of micropapillary-related subtypes and development of a prognostic model
Presenter: Yuechun Lin
Session: Poster session 04
1276P - Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Kiyotaka Yoh
Session: Poster session 04